The global malignant pleural effusion market is expected to garner a market value of USD 4.5 Billion in 2023 and is expected to accumulate a market value of USD 8.06 Billion by registering a CAGR of 6% in the forecast period 2023 to 2033. The increasing incidence of pleural effusion disease and rising awareness of advancement in pleural effusion treatment with different types of techniques in the current market works as a driver for the market. The market for Malignant Pleural Effusion registered a CAGR of 4% in the historical period 2018 to 2022.
Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period. Recent epidemiological data from WHO suggests that approximately more than one million pleural effusions are diagnosed in the United States each year.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 4.5 Billion |
| Anticipated Forecast Value (2033) | USD 8.06 Billion |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
According to market research and competitive intelligence provider Future Market Insights. the market for Malignant Pleural Effusion reflected a value of 4% during the historical period, 2018 to 2022. Various factors such as awareness in wellness and health, the diagnostics, and pathology segment are improving in developing countries nowadays which grows the therapeutics market. The research and development activities in the field like emerging novel therapeutics, increasing the efficacy of medicine as well as treatment.
Selling campaigns initiated by global players are growing the market progressively. Increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of pleural effusions is fuelling market growth. Thus, the market for Malignant Pleural Effusion is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Increasing Incidence of Malignant Pleural Effusion disease post covid-19 pandemic to push the market growth
The increasing prevalence of Malignant Pleural Effusion disease is one of the biggest drivers of the market. After The covid-19 pandemic hit the world, various research was conducted to find a correlation between Covid-19 infection and pleural effusion.
For instance, the article “Prevalence and Clinical Outcomes of Pleural Effusion in Covid-19 Patients: A Systematic Review and Meta-Analysis” published in January 2022 showed that pleural effusion is related to the risk and prognosis of Covid-19 disease.
Pleural effusion can be used as a prognostic indicator to assess the likelihood of poorer outcomes in Covid-19 patients; as a result, the researchers of the above-mentioned research article advised that hospitalized Covid-19 patients with pleural effusion be handled promptly. Considering these in-depth studies, the pandemic showed a considerable impact on the market studied.
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Malignant Pleural Effusion, less awareness of Malignant Pleural Effusion disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Malignant Pleural Effusion in Asia Pacific
The Asia Pacific is expected to exhibit the fastest growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of malignant pleural effusion in the region.
Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the Pleural effusions treatment market worldwide.
High Prevalence of various diseases shaping the landscape for Malignant Pleural Effusion in North America
North America is anticipated to acquire a market share of about 45% in the forecast period. This growth is attributable to the rising prevalence of pleural effusions in the region. An article published by WebMD LLC in October 2021 stated that approximately 1.5 million pleural effusions are diagnosed in the United States every year and in industrialized countries, the estimated prevalence of pleural effusion is 320 cases per 100,000 people.
This ever-widening burden of the condition on the healthcare facilities is creating demand for the treatment globally, expected to fuel the market growth during the analysis period. Furthermore, the rising geriatric population is leading to an increase in the prevalence of various diseases, growing the health and economic burden.
As per the American Heart Association data updated in April 2022, nearly 115 million people in have hypertension, 100 million have obesity, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic cardiovascular diseases (CVD) United States, which are known to be the risk factors for the development of heart failure. Thus, the high burden of various diseases creates the risk of pleural effusions among the target population in the United States.
Key start-up players in the Malignant Pleural Effusion market are-
Key players in the Malignant Pleural Effusion market are Allakos, iCo Therapeutics, Akari Therapeutics, and Santen.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 4.5 Billion |
| Market Value in 2033 | USD 8.06 Billion |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment, End User, Diagnosis, Region |
| Regions Covered | North America; Latin America; Western Europe; Eastern Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, BENELUX, France, Germany, Italy, Nordics, Spain, The UK, Poland, Russia, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | B. Braun SE; Becton, Dickinson, and Company; Bicakcilar; Biometrix; Cook Medical; Grena; Redax; Rocket Medical; Smith Medical; Taiho Pharmaceutical Co. Ltd. |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Western Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 15: Western Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Eastern Europe Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 19: Eastern Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 21: APAC Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: APAC Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 23: APAC Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 24: APAC Market Value (US$ Million) Forecast by End User, 2018 to 2033
Table 25: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: MEA Market Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 27: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033
Table 28: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 17: Global Market Attractiveness by Diagnosis, 2023 to 2033
Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033
Figure 19: Global Market Attractiveness by End User, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 37: North America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033
Figure 39: North America Market Attractiveness by End User, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Diagnosis, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033
Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Western Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 62: Western Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Western Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 71: Western Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 77: Western Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 78: Western Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033
Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: Eastern Europe Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 82: Eastern Europe Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033
Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 97: Eastern Europe Market Attractiveness by Diagnosis, 2023 to 2033
Figure 98: Eastern Europe Market Attractiveness by Treatment, 2023 to 2033
Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033
Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 101: APAC Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 102: APAC Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 103: APAC Market Value (US$ Million) by End User, 2023 to 2033
Figure 104: APAC Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: APAC Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: APAC Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: APAC Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: APAC Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 109: APAC Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 110: APAC Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 111: APAC Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 112: APAC Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 113: APAC Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 114: APAC Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 115: APAC Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 116: APAC Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 117: APAC Market Attractiveness by Diagnosis, 2023 to 2033
Figure 118: APAC Market Attractiveness by Treatment, 2023 to 2033
Figure 119: APAC Market Attractiveness by End User, 2023 to 2033
Figure 120: APAC Market Attractiveness by Country, 2023 to 2033
Figure 121: MEA Market Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 122: MEA Market Value (US$ Million) by Treatment, 2023 to 2033
Figure 123: MEA Market Value (US$ Million) by End User, 2023 to 2033
Figure 124: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: MEA Market Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 129: MEA Market Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 130: MEA Market Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 131: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033
Figure 132: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033
Figure 133: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033
Figure 134: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033
Figure 135: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033
Figure 136: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033
Figure 137: MEA Market Attractiveness by Diagnosis, 2023 to 2033
Figure 138: MEA Market Attractiveness by Treatment, 2023 to 2033
Figure 139: MEA Market Attractiveness by End User, 2023 to 2033
Figure 140: MEA Market Attractiveness by Country, 2023 to 2033
From 2017 to 2022, the Malignant Pleural Effusion market grew at a CAGR of 4%.
The global Malignant Pleural Effusion market is expected to grow with a 6% CAGR from 2023 to 2033.
As of 2033, the Malignant Pleural Effusion market is expected to reach USD 8.06 Billion
According to the FMI analysis, hospitals account for the largest market share.
North America is expected to possess a 45% market share for the Malignant Pleural Effusion market.
The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
Malignant Pleural Effusion Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
